APA (7th ed.) Citation

AB, C., & C, O. (2026). Inter-assay variability in anti-JC virus serology in the era of natalizumab biosimilars: Implications for PML risk stratification. Frontiers in immunology, 17, 1818341. https://doi.org/10.3389/fimmu.2026.1818341

Chicago Style (17th ed.) Citation

AB, Caminero, and Oreja-Guevara C. "Inter-assay Variability in Anti-JC Virus Serology in the Era of Natalizumab Biosimilars: Implications for PML Risk Stratification." Frontiers in Immunology 17 (2026): 1818341. https://doi.org/10.3389/fimmu.2026.1818341.

MLA (9th ed.) Citation

AB, Caminero, and Oreja-Guevara C. "Inter-assay Variability in Anti-JC Virus Serology in the Era of Natalizumab Biosimilars: Implications for PML Risk Stratification." Frontiers in Immunology, vol. 17, 2026, p. 1818341, https://doi.org/10.3389/fimmu.2026.1818341.